论文部分内容阅读
β-内酰胺类抗生素(半合成青霉素类和头孢菌素类)在产科临床上广泛使用的重要原因是其毒性低,对胎儿无不良作用,抗菌谱广和具有杀菌作用。然而,随着新β-内酰胺类的使用,对其耐药的菌株日益增多。耐药性的产生与细菌产生水解抗生素β-内酰胺环的β-内酰胺酶有关。目前已确定,产生新型β-内酰胺酶的潜在可能性尚未得到控制。因此,研制半合成青霉素与β-内酰胺酶抑制剂的复合剂是很有前途的。《Unasyn》是美国费歇尔公司生产的氨苄青霉素与β-内酰胺酶抑制剂舒巴克坦复合剂(A/S)的商品名。舒巴克坦是青霉素核的衍生物,它与细菌产生的β-内酰胺酶不可解
β-lactam antibiotics (semisynthetic penicillins and cephalosporins) widely used in obstetric clinics important reason is its low toxicity, no adverse effects on the fetus, broad antibacterial spectrum and has a bactericidal effect. However, as new β-lactams are used, the number of strains resistant to them is increasing. Drug resistance is associated with the bacterial production of β-lactamases that hydrolyze the antibiotic β-lactam ring. It has now been determined that the potential for producing novel β-lactamase has not yet been controlled. Therefore, the development of semi-synthetic penicillin β-lactamase inhibitor complex is very promising. “Unasyn” is the trade name of ampicillin and the β-lactamase inhibitor, sulbactam complex (A / S) manufactured by Fischer Pharmacy. Sulbactam is a derivative of the penicillin nucleus, which is not hydrolyzable to the β-lactamase produced by the bacteria